A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
WHO International Clinical Trials Registry Platform - (2022) vom: 16. Mai Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 25-11-2021, Last updated: 2022-11-24 |
|---|
| ICTRP ID: |
EUCTR2021-000044-22-NO |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CTG008455422 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG008455422 | ||
| 003 | DE-627 | ||
| 005 | 20230425181712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220512s2022 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)CTG008455422 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)EUCTR2021-000044-22-NO | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)C1071005 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)NCT05020236 | ||
| 035 | |a (UBBS_Klinische_Studien_WHO)2021-000044-22-SE | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 245 | 1 | 0 | |a A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |b AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 25-11-2021, Last updated: 2022-11-24 | ||
| 650 | 4 | |a Medical Condition: MULTIPLE MYELOMA MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Phase: Phase 3 | |
| 650 | 4 | |a Recruitment Status: Authorised-recruitment may be ongoing or finished | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t WHO International Clinical Trials Registry Platform |g (2022) vom: 16. Mai |
| 773 | 1 | 8 | |g year:2022 |g day:16 |g month:05 |
| 856 | 4 | 0 | |u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000044-22 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 16 |c 05 | ||